Agomelatine in the Treatment of Major Depressive Disorder: An Assessment of Benefits and Risks

ISSN: 1875-6190 (Online)
ISSN: 1570-159X (Print)


Volume 12, 6 Issues, 2014


Download PDF Flyer




Current Neuropharmacology

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 121st of 254 in Pharmacology & Pharmacy

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
T.E. Salt
University College London
Institute of Ophthalmology
London EC1V 9EL
UK


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.347
5 - Year: 3.856

Agomelatine in the Treatment of Major Depressive Disorder: An Assessment of Benefits and Risks

Author(s): Maximilian Gahr

Affiliation: Department of Psychiatry III, University of Ulm, Leimgrubenweg 12-14, 89075 Ulm, Germany

Abstract

Agomelatine (AGM) was approved for the treatment of major depressive disorder (MDD) in adults by the European Medicines Agency (EMA) in February 2009. It is an analogue of melatonin and features a unique pharmacodynamic profile with agonism on both types of melatonergic receptors (MT1/MT2) and antagonism at serotonergic 5-HT2C receptors. There is, however, an ongoing debate regarding the efficacy and safety of this novel antidepressant agent, originally evoked by claims of a significant publication bias underlying the assessment of AGM being an effective antidepressant. Indeed, two recent comprehensive metaanalyses of published and unpublished clinical trials found evidence for a relevant publication bias. However, due to its statistically significant advantage over placebo based on the results of these metaanalyses AGM must be referred to as an effective antidepressant agent in the acute phase of MDD. However, the effect sizes of AGM in the treatment of MDD were evaluated as being small in comparison to other antidepressant agents. In addition, there is insufficient evidence for the efficacy of AGM in relapse prevention of MDD. Apart from efficacy issues, AGM appears to have the potential to exhibit severe hepatotoxicity (the EMA has identified AGM-associated “hepatotoxic reactions” as a new safety concern in September 2013) that is currently poorly understood. Considering these aspects, it seems inappropriate to evaluate AGM as an antidepressant agent of first choice. Nevertheless, its unique mechanism of action with particular sleep modulating effects may represent a specific treatment strategy for patients with particular characteristics; further studies with thorough characterization of patients are needed to test this hypothesis.

Keywords: Adverse drug reaction, antidepressant, hepatopathy, liver enzymes, melatonin, pharmacovigilance, S20098

Purchase Online Rights and Permissions

  
  



Article Details

Volume: 12
First Page: 1
Last Page: 11
Page Count: 11
DOI: 10.2174/1570159X12999140619122914
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science